TB Alliance and BioFocus Sign Compound Management Agreement
News Jan 11, 2010
BioFocus announced that it has signed a three year compound management agreement with the Global Alliance for TB Drug Development (TB Alliance).
Under this agreement BioFocus will manage TB Alliance’s chemical library collection. These services will be provided by BioFocus’ compound management facility in South San Francisco, USA.
“We are pleased to welcome TB Alliance as a new client to our compound management services, joining other prestigious names such as the National Institutes of Health,” said Scott Snyder, BioFocus’ Senior Director, Compound Management. “This collaboration leverages our full suite of compound management services and further expands our client base of not-for-profit discovery organizations to a global level.”
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer’s disease – even before they show signs of confusion and memory loss, according to a new study from Washington University School of Medicine in St. Louis and the German Center for Neurodegenerative Diseases in Germany.READ MORE
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE